Tags

Type your tag names separated by a space and hit enter

Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Int J Antimicrob Agents. 2020 04; 55(4):105933.IJ

Authors+Show Affiliations

Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance 7 Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 8 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.Department of Infectious Diseases, Chang Gung Memorial Hospital, Taoyuan, Taiwan.Department of Pediatrics, National Taiwan University Children's Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsporen@ntu.edu.tw.

Pub Type(s)

Editorial

Language

eng

PubMed ID

32147516

Citation

Ko, Wen-Chien, et al. "Arguments in Favour of Remdesivir for Treating SARS-CoV-2 Infections." International Journal of Antimicrobial Agents, vol. 55, no. 4, 2020, p. 105933.
Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020;55(4):105933.
Ko, W. C., Rolain, J. M., Lee, N. Y., Chen, P. L., Huang, C. T., Lee, P. I., & Hsueh, P. R. (2020). Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 55(4), 105933. https://doi.org/10.1016/j.ijantimicag.2020.105933
Ko WC, et al. Arguments in Favour of Remdesivir for Treating SARS-CoV-2 Infections. Int J Antimicrob Agents. 2020;55(4):105933. PubMed PMID: 32147516.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Arguments in favour of remdesivir for treating SARS-CoV-2 infections. AU - Ko,Wen-Chien, AU - Rolain,Jean-Marc, AU - Lee,Nan-Yao, AU - Chen,Po-Lin, AU - Huang,Ching-Tai, AU - Lee,Ping-Ing, AU - Hsueh,Po-Ren, Y1 - 2020/03/06/ PY - 2020/02/16/received PY - 2020/02/28/revised PY - 2020/3/10/pubmed PY - 2020/4/30/medline PY - 2020/3/10/entrez KW - Betacoronavirus KW - COVID-19 KW - Coronavirus disease 2019 KW - Remdesivir KW - SARS-CoV-2 KW - Wuhan pneumonia SP - 105933 EP - 105933 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 55 IS - 4 SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/32147516/Arguments_in_favor_of_remdesivir_for_treating_SARS-CoV-2_infections L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(20)30083-2 DB - PRIME DP - Unbound Medicine ER -